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CHAPTER 1 INTRODUCTION
Heart diseases are the leading killer of both men and women in the United States.
Abnormalities in the cardiac contractile proteins are one of the major causes for heart diseases
and can result in severe cardiac dysfunction such as heart failure. For example, hypertrophic
cardiomyopathy (HCM), which affects up to 1 in 500 of the population, is the most frequently
occurring inherited cardiac disease1. HCM has been linked to the expression of abnormal
contractile proteins: myosin heavy chain, tropomyosin, troponin T and troponin I 2,3,4,5. Heart
failure, the pathophysiological state in which blood delivery is insufficient for tissue requirements
due to weakened contraction of cardiac muscle, is the most common cause of morbidity and
mortality of heart diseases. Approximately five million people in the United States currently
suffer from congestive heart failure with 1.4 million under 60-year-old of age. More than 5% of
the population aged 60 to 69 has heart failure. More than half a million new cases are diagnosed
each year and near 300,000 annual deaths are due to heart failure. Despite the significant
advances in pharmacological and clinical treatment of heart disease, heart failure remains a major
medical challenge worldwide. As such, further understanding the molecular mechanisms of by

which cardiac contractile proteins regulate heart contraction would provide new therapeutic
targets and/or strategies.

2

My research project focuses on the detailed molecular mechanism of regulation of
Ca2+dependent cardiac muscle contraction by troponin, a protein complex that is associated with
the myofilaments in muscle cells. The primary function of troponin is the Ca2+-regulated inhibition
of actomyosin ATPase. Troponin plays a vital role in the contraction and relaxation of striated
muscles. The function and regulation of troponin subunits cTnI and cTnT is critical to cardiac
physiology and many heart diseases. Recent studies have shown that the N-terminal domains of
cardiac troponin I (cTnI) and cardiac troponin T (cTnT) can be selectively removed by restrictive
proteolysis during cardiac adaptation to physiological and pathological stresses, indicating that
the N-terminal domains of these cTn subunits selectively regulate diastolic and systolic functions
of the heart. In this study, by using intact myofibrils isolated from genetically modified mouse
hearts, I will characterize the effects of modifications of troponin subunit cTnI and cTnT on the
kinetics properties of myosin ATPase cycle, the foundation of cardiac power generation.
Therefore, this study will connect a gap in the
understanding of the molecular regulation of cardiac
muscle contractility, and adaptation in congestive
heart failure, and maybe useful for the development
Figure 1 Basic structure of cardiac muscle

of new treatment for heart failure.
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CHAPTER 2 CARDIAC MUSCLE STRUCTURE AND TROPONIN COMPLEX

Figure 2. Structure of the sarcomere. A, An electron micrograph of longitudinal section of mouse
striated muscle showing one complete labeled sarcomere. (Lodish, Molecular Cell Biology, 4th Edition,
2001) B, The basic units of the sarcomere: Thick filament—myosin, thin filament—actin, tropomyosin,
and troponin complex, and the Z disc, which delineates a single sarcomere.
http://class.fst.ohio-state.edu/FST822/lecturesab/Muscl.htm

Proper cardiac muscle contraction is crucial for keeping normal heart function. The
cardiac muscle is composed of cardiac muscle cells (cardiomyocytes) that contain myofibrils
formed by tandemly connected sarcomeres that are the contractile elements of the heart. At the
microscopic level, the myocardium forms a branched structure, with each cardiomyocyte in
contact with the next via intercalated disks (Fig. 1). Gap junctions exist within the intercalated
disks, allowing a rapid passage of ions from cell to cell, creating an action potential that is
propagated throughout the entire organ as a coordinated heart contraction. Cardiac muscle is
striated, these microscopically visible striations are a result of the organization of thick and thin
filaments (see below) of contractile myofibrillar proteins in the sarcomeres (Fig. 2). The thick
filament extends the length of the sarcomere A-band and is primarily composed of the motor
protein myosin II. The thin filaments extend the length of the I-bands, and are primarily
composed of filamentous actin and the regulatory proteins troponin (Tn) and tropomyosin (Tm).
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The Z-disk bisects each I-band, and sets the outer limits for each sarcomere unit. Many other
proteins are associated with the sarcomere and participate with actin and myosin in efficient
muscle contraction. These proteins include, but are not limited to, titin, myosin binding protein
C, M-protein, myomesin, tropomodulin, and Cap-Z6.
2.1 THICK FILAMENT
The thick filament is comprised of many proteins that affect its structure as well its
function (e.g. myosin II and myosin binding protein C). However, the major component of most,
but not all, thick filaments is myosin II. Myosin molecules are characteristically long proteins with
a well conserved N-terminus and a C-terminus that is specific to its class. It is composed of two
heavy chains of mass ~200 kDa each, two regulatory light chains and two essential light chains,
each of which are ~20 kDa. The two HCs intertwine to form a long alphahelical coiled coil tail (Cterminus) and two globular motor domains (N-terminus), also termed heads or S1 (subfragment
1) with an overall length of approximately 150 nm. One pair of light chains binds to each head.
The alpha-helical coiled-coil regions of myosin II are subjected to filament formation due to the
interactions between pseudo repeats of oppositely charged amino acids in the coiled-coil regions
with molecules shifted by a regular interval along the filament of ~14.3 nm7. When subjected to
proteolytic activity, the myosin is cut into two different fragments, the light meromyosin that
makes up majority of the myosin tail, and heavy meromyosin that consists of the rest of the tail
and the globular heads. The globular head has an ATPase activity which is activated by actin.
Myosin binding protein C also plays an important role in thick filament structure. It has
been shown to bundle myosin II molecules together during development 8. Partially associated
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with the thick filament, the long elastic molecule titin has also been shown to have structural
importance by providing sarcomere stability as well as passive flexibility9.
2.2 THIN FILAMENT
The thin filament apparatus is composed of three main proteins: actin, tropomyosin and
the troponin complex. Of the three, actin forms the backbone of the thin filament and is the most
conserved contractile protein10. Actin is found in two different forms: globular (G) and
filamentous (F). In muscle, G-actin monomers polymerize to make F-actin which in turn makes
up the actin filament in a sarcomere. Kabsch et al11 first determined the structure of G-actin to
be composed of two different domains, each of which can be divided into two subdomains
(named one through four). In their proposed filament model, subdomains 3 and 4 are oriented
to the inside of the filament allowing them to interact with the same subdomains of another
monomer. Meanwhile, subdomains 1 and 2 are exposed to the surface and are able to interact
with the myosin head. Also, G-actin is an ATPase with an ATP binding site in the center of the
monomer, which is essential for the polymerization of G-actin to F-actin. One F-actin helix
consists of 13 molecules of G-actin in six turns of the helix, which repeat every 360 Angstroms12.
Tropomyosin is about 42 nm long13 and consists of 284 amino acids with a repeated
heptapeptide. Tropomyosin is known to form a homodimer or heterodimer of two alpha helical
chains arranged as a coiled-coil, stabilized by hydrophobic and ionic interactions between each
chain. The protein lies along the actin filament with the N-terminus of one dimer interacting with
the C-terminus of the following dimer (head-to-tail configuration). Each chain spans seven actin
monomers on the F-actin filament. The binding of tropomyosin to actin is the key in muscle
contraction and is affected by numerous factors such as the presence of the troponin complex as
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well as the myosin head. Furthermore, the interaction is greatly disrupted if the overlapping
head-to-tail region is absent14.
Another major thin filament protein is the troponin complex, which is distributed at
intervals of 38 nm along the filament15,16 and associates with tropomyosin in a 1:1 ratio. It is
composed of three interacting subunits including troponin C (TnC), troponin I (TnI) and troponin
T (TnT).
2.3 TROPONIN C
Troponin C (TnC) is the Ca2+ binding subunit of the troponin complex. The crystal structure
of TnC reveals a dumbbell-shaped protein consisting of two globular domains, joined by a 22residue central α-helix17,18,19. Each domain contains a hydrophobic cleft and two helixloop-helix
EF-hand metal binding motifs. The C-terminal domain consists of the two highaffinity (K~10 7 M1)

Ca2+/Mg2+ sites (sites III and IV) while the N-terminal consists of the two low-affinity (K~105 M-

1) Ca2+ specific sites (sites I and II). However, the calcium binding site I of the cardiac TnC is inactive

due to amino acid insertion and substitution in this site20, therefore cTnC only binds three Ca2+
ions as opposed to four as in the skeletal isoform. Calcium induces a conformational change in
TnC, hence producing structural changes between the thin filament proteins. These structural
changes therefore lead to the interactions of the thin filament proteins with the thick filament
proteins.
2.4 TROPININ I
Troponin I is the inhibitory subunit of the troponin complex that inhibits the actomyosin
ATPase activity. The Ca2+ dependent inhibition of TnI requires TnC, TnT and tropomyosin. When

in the absence of Ca2+, TnI binds weakly with TnC (K~ 106M-1), and binds actin strongly through
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its inhibitory actin binding sites. In the presence of Ca2+, the interaction between TnC and TnI is
enhanced (K~109M-1) and the main inhibitory domain of TnI dissociates from actin, initiating
contraction.
Troponin I exists in three muscle specific isoforms: fast skeletal TnI, slow skeletal TnI and
cardiac TnI. TnI isoform gene expression is controlled at the transcription level, which is regulated
by fiber type specificity and development. Accordingly, slow skeletal muscle fibers only express
the slow TnI isoform, whereas fast skeletal muscle fibers only express the fast TnI isoform.
However, the expression of TnI isoforms in cardiac muscle shows a developmental regulation.
During the embryonic stages of the heart, the slow skeletal isoform is expressed and then
switches off during development, whereas the cardiac isoform is upregulated and eventually
replaces all the slow skeletal troponin I in the adult heart21-23. Previous studies showed that there
was a decreased sensitivity to acidosis in newborn rabbit hearts when compared to that of adult
hearts, as well as the myofibrillar calcium activation being insensitive to acidosis in perinatal dog
hearts24. Thus, this transition was believed to occur because of the different troponin isoforms
that exist in the neonatal heart as opposed to the adult heart.
The amino acids of all TnI isoforms are highly conserved, except for a 32 residue extension
in the N-terminal unique to the cTnI across all species. This unique 32 amino acid extension
contains two serine residues (Ser-23/Ser-24 in human and Ser-22/Ser-23 in mouse) that are the
targets for phosphorylation by protein kinase A upon beta-adrenergic stimulation. This
physiological stimulation occurs in response to an increasing demand of blood circulation in the
body. Studies have shown that phosphorylation of these serine residues of cTnI by PKA decreases
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the myofibrillar Ca2+ sensitivity of force development and increases the rate of force relaxation,
therefore enhancing diastolic function by reducing the Ca2+ binding affinity of TnC25,26.
In addition to the phosphorylation modifications that occur at specific amino acid residues
throughout cardiac troponin I, proteolytic modifications to the C-terminus and Nterminus can
also occur, both having distinct effects on cardiac function. Further investigations have found
that selective removal of the N-terminal extension by restricted proteolysis occurs during
hemodynamic stress adaptations27,28. Specifically, the restrictive proteolysis of the N-terminal
extension of cardiac troponin I is an adult specific regulatory structure 29. This truncation occurs
as an adaptation mechanism in adult hearts in response to physiological and pathological stress
conditions.
Subsequently, genetic removal of the N-terminal extension in the heart of mice mimics
the effects of PKA phosphorylation as a compensation for β-adrenergic deficiency, and showed
decreased Ca2+ sensitivity, enhanced ventricular relaxation30 and improved cardiac function in
aged animals31. At the molecular level, the N-terminal extension of cTnI has been reported to
regulate the calcium sensitivity of cross-bridge cycle (see below) and decreased steady state
ATPase activity of skinned myofibrils, which partially accounts for the enhanced relaxation and
improved cardiac functions32,33,34,35. However, at the molecular level, how the N-terminal
extension of cTnI regulates the cross bridge cycling of myofilaments to enhance cardiac muscle
relaxation is not fully understood.
2.5 TROPONIN T
Troponin T plays a major role in linking the three subunits of the troponin complex and in
mediating the effect of calcium activation to tropomyosin. Being the largest component of the
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troponin complex, it is a 30-35 kDa rod-shaped protein of about 17 nm in length with many
different variants generated by alternative RNA splicing. The size of TnT can vary anywhere from
223 to 305 amino acids in vertebrates, primarily due to the size of the variable N-terminal
region36. The central region of TnT binds strongly to the head tail junction of tropomyosin and is
responsible for the cooperative transition of the thin filament. The C-terminal region of TnT binds
to TnI, TnC, F-actin and the central region of tropomyosin. Troponin T plays a critical role as an
anchoring protein and is important for calcium-sensitive action37.
Much like troponin I, troponin T exists in three muscle specific isoforms: fast skeletal
troponin T, slow skeletal troponin T and cardiac troponin T. Expression of TnT genes is also
controlled at the transcription level, which is regulated by fiber type specificity and
development36,38. The core amino acid sequences among the isoforms are highly conserved
among the isoforms, of which the C-terminal region contains binding sites for TnC, TnI, and
tropomyosin and the central region of TnT contains a second tropomyosin-binding site. The Nterminal region of TnT does not contain any known protein binding sites.
The

different

TnT

isoforms mainly differ in their
N-terminal variable region. In
Figure 3. Stick figure representation of f troponin T isoforms.
Wei et al 2014

cardiac

TnT,

studies

have

shown that during myocardial

ischemia reperfusion, this variable region is selectively removed by µ-calpain proteolysis39.
Aberrant splicing of the N-terminal variable region is found in human failing hearts. It is thought
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that the variable region of cTnT is a target for proteolysis by µ-calpain as a means to modify the
kinetics of cardiac contraction, specifically decreasing the rate of contraction, and increase
energetic efficiency in order for the heart to sustain function during heart failure 28.
Genetic removal of this N-terminal variable region in the heart decreases the maximal
force and increases the affinity of troponin to tropomyosin39. As a mediator of Ca2+ regulation
during muscle contraction, deletion of the variable region exhibits no change in the activity of
TnT in Ca2+ activation of the thin filament40 as well as the regulation of actomyosin ATPase41,42.
However, even though the regulatory activity remains unchanged, TnT’s overall protein
conformation43,44 is affected and binding affinity to Tm increases42 due to the deletion. The
molecular mechanism for the N-terminal variable region of cTnT to regulate cardiac contraction
is not fully understood.
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CHAPTER 3 CARDIAC MUSCLE CONTRACTION AND ACTOMYOSIN ATPASE CYCLE
Regulation of contraction in cardiac muscles depends on the thin filament proteins,
troponin and tropomyosin. Troponin associates with the tropomyosin dimer in a 1:1 ratio, and
each tropomyosin-troponin complex spans and regulates seven actin monomers. In the relaxed

A
..

state when Ca2+ level is low (<10-8M), TnI
binds strongly

to

actin,

so

that

tropomyosin is held in a blocking position

B

which covers the myosin binding sites on
the

actin

filament.

When

the

Ca2+ concentration rises to activating
levels (>10-6M), the binding of Ca2+ to
troponin causes tropomyosin to move
from its blocking position of myosin on
actin, allowing the cyclic interaction of
myosin to cross-bridge with actin for
muscle contraction.
The cooperative process of the
actomyosin cross-bridge binding kinetics
Figure 4. The ATPase cycle. A minimal mechanochemical is important in the cardiac muscle as a
scheme for the actomyosin cross-bridge cycle. Actin
monomers are shown as golden spheres. The motor
determinant of systolic and diastolic
domain is colored metallic grey for the free form, purple
for the weakly bound form and violet for the strongly
bound form. The converter is shown in blue and the lever functions. To understand the calcium
arm in orange.

regulation of cardiac actomyosin cross-
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bridge interactions, it is important to look at the steps involved in cross-bridge cycling and force
generation. Figure 4 reproduced from Geeves et al45 illustrates the individual steps during the
actomyosin ATPase cycle. The steps taken by myosin and actomyosin are shown in the top
(Figure 4A) and bottom (Figure 4B), respectively. Both pathways show a slew of events occurring:
ATP (T) binding, ATP hydrolysis, inorganic phosphate release (Pi) and finally ADP (D) dissociation.
Fig. 4B depicts a very basic ATPase scheme followed by actomyosin. The scheme begins in state
a, where the myosin is strongly bound to actin (rigor complex). In the presence of ATP (state b),
myosin quickly dissociates from actin and shifts its lever arm back into the pre-power stroke
position. Myosin then hydrolyzes ATP to ADP and Pi, thus permitting the M.D.Pi complex to bind
to actin weakly (state c) and then strongly (state d). Once bound to actin, Pi dissociates and the
power stroke occurs (state e). The completion of the power stroke initiates ADP dissociation
(state f) and the cycle has completed one complete rotation back to the rigor complex.
During contraction, Ca2+, as well as the number of strongly bound cross-bridges,
accelerates the forward rate constant for going from state c to state d. This acceleration is due
to calcium binding to cTnC, resulting in a conformation change in tropomyosin and ultimately
exposing myosin binding sites on actin. In resting muscle (absence of Ca2+), tropomyosin blocks
the myosin binding sites on actin. Tropomyosin is "locked" down in this position by troponin T
and troponin I, inhibiting myosin from strongly binding to actin.
Although the actomyosin cross-bridge cycling is initiated by the rise of sarcomeric calcium
in the muscle cells, phosphorylation of titin, myosin-binding protein C (MyBP-C), and cTnI by PKA
also play important roles in regulating the actomyosin cross-bridge activity in cardiomyocytes.
Increased β-adrenergic tone stimulates PKA activities, resulting in faster velocity of relaxation,
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lower left-ventricular end diastolic pressure, increased left-ventricular end diastolic volume, and
higher stroke volume26,25,35,28,46. The effects due to phosphorylation of MyBP-C by PKA on
actomyosin interaction have been studied, but no significant change in myofibril ATPase was
found34,47.
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CHAPTER 4 ENZYME KINETICS
4.1 MICHAELIS-MENTEN KINETICS
When two molecules are in solution, random thermal movements can cause these
molecules to collide. If the two molecules have very poorly matching surfaces, they will most
likely form very few noncovalent bonds and are likely to dissociate very quickly. However, if they
have better matching surfaces, the two molecules will form more noncovalent bonds and will
remain bound to each other for a long period of time. The population of bound molecules will
then continue to increase, but not without limit, as over time the two molecules will start to
dissociate. However, there will eventually be a point in time where the number of association
events will equal the number of dissociation events. Therefore, the equilibrium constant (K) can
be calculated from the concentration of each molecule (ligand/substrate and protein) and from
the substrate-protein complex. Thus, the equilibrium constant is a measure of how strong the
two molecules are bound together. Half the number of binding sites will be occupied by ligand
when the ligand’s concentration (moles/liter) becomes equal to 1/K. The equilibrium constant is
also known as the affinity or association constant. The larger the equilibrium constant, the larger
the binding strength.
When a protein is able to catalyze a chemical reaction, it is called an enzyme. Enzymes
can only process a limited amount of substrate in a given time, therefore increasing the
concentration of substrate can increase the rate in which the product complex is formed, up to a
maximum value. Here the reaction is written as:
𝑘𝑐𝑎𝑡

𝐸+𝑆⇌𝐸𝑆→ 𝐸+𝑃

(1)
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At this point, the enzyme is now saturated with substrate and the reaction rate Vmax now depends
on how fast the enzyme can process the substrate. The turnover number, kcat, is equal to Vmax
divided by the enzyme concentration and is the rate constant that is equal to the number of
substrate molecules processed per enzyme per second. When in steady state, the concentration
of [ES] is nearly constant so that
𝑘−1[𝐸𝑆]+𝑘𝑐𝑎𝑡[𝐸𝑆]=𝑘1[𝐸][𝑆]

(2)

And,
[𝐸]=[𝐸0]−[𝐸𝑆]

(3)

Where [Eo ] is the initial amount of enzyme, [E] is the concentration of free enzyme and [ES] is the
concentration of enzyme-substrate complex. By inserting (3) into (2), (2) can now be rewritten as

[𝐸𝑆]=(𝑘

𝑘1
−1 +𝑘𝑐𝑎𝑡

)[𝐸][𝑆]=( 𝑘

𝑘1
−1 +𝑘𝑐𝑎𝑡

)([𝐸𝑜]+[𝐸𝑆])[𝑆]

(4)

Therefore, if we set (𝑘−1𝑘+1𝑘𝑐𝑎𝑡)=𝐾𝑚 and 𝑉𝑚𝑎𝑥 =𝑘𝑐𝑎𝑡[𝐸𝑜], then (4) can be rewritten as

𝑉=𝑘𝑐𝑎𝑡[𝐸𝑆]=

𝑘𝑐𝑎𝑡 [𝐸𝑜 ][𝑆]
𝐾𝑚 +[𝑆]

=

𝑉𝑚𝑎𝑥 [𝑆]
𝐾𝑚 +[𝑆]

(5)

Which is the Michaelis-Menten equation. It is one of the best known models of enzyme kinetics
and is named after German biochemist Leonor Michaelis and Canadian physician Maud
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Menten. The concentration at which the reaction is half its maximum value is known as Km. High
Km means that the enzyme reaches its maximum catalytic rate at a high concentration and
generally indicates that the enzyme binds its
substrate very weakly.
4.2 HILL EQUATION
The Hill equation was first derived by
Archibald Hill in 1910 to describe the sigmoidal
binding of oxygen (O2) to hemoglobin48. More
generally, it describes cooperative binding, which
Figure 5. Sample plots of cooperative and
hyperbolic response curves. Blue line
represents Michaelis-Menten curve and red
line represents Hill kinetics

occurs when a ligand binds to a molecule in the
presence of other already bound ligands. These

already bound ligands can enhance the binding of the new ligand (Fig. 5). The Hill equation has
the following form:
𝜃=

[𝑳]𝒏
𝑲𝒅 +[𝑳]𝒏

=

[𝑳]𝒏
(𝑲𝑨 )𝒏 +[𝑳]𝒏

Where θ is the percentage of binding sites that are occupied by ligand, [L] is the concentration of
free ligand, Kd is the equilibrium dissociation constant, KA is the concentration of ligand occupying
half the binding sites and n is the Hill coefficient, which defines the cooperativity as previously
described. The Hill coefficient can have one of three forms. When n is greater than 1, the affinity
for other ligand molecules increases when a subsequent ligand has already bound to the enzyme.
When n is less than 1, the affinity for the other ligand molecules decreases when a subsequent
ligand has already bound to the enzyme. Finally, when n is equal to 1, the affinity is then
independent if other ligand molecules are bound to the enzyme or not.
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Therefore, the Hill equation is a good model to represent simple cooperative systems.
However, there are some limitations of the model. The Hill coefficient should also represent the
number of binding sites on the enzyme, but since it is normally not an integer number, some
argue that it is not a good model to represent a real system.
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CHAPTER 5 MATERIALS AND METHODS
5.1 SDS-PAGE AND WESTERN BLOT
The protein extracts from ventricle of each mouse heart was separated by
SDSpolyacrylamide gel electrophoresis (PAGE) followed by Western-blotting to confirm the gene
type and the presence of 100% cTnI-ND or cTnT-ND in the transgenic mouse hearts as described
previously49. Briefly, the muscle samples were homogenized in SDS-sample buffer and analyzed
on 14% gel with acrylamide:bisacrylamide ratio of 180:1. The protein bands resolved were
stained with Coomassie Blue R250 or transferred to nitrocellulose membrane for blotting using
either monoclonal antibody TnI-1 recognizing both cTnI and cTnI-ND or CT3 to recognize cTnTND.
Aliquots of the cardiac myofibrils used in the kinetic studies were also examined to verify the
protein integrity after processing under the isolation and assay conditions.
5.2 MYOFIBRIL PURIFICATION
Cardiac myofibrils were prepared using a modified method as previously described 50,51,52.
Briefly, the frozen mouse heart was thawed on ice and minced into small pieces, followed by
homogenized in five volumes of ice-cold Rigor buffer (10 mM Tris-HCl, pH 7.0, 5 mM EGTA, 130
mM NaCl, 5 mM KCl, 1 mM MgCl2, 1 mM NaN3, 1 mM DTT, 0.1 mM PMSF, 1 µM Papstatin A and
1 µg/mL Leupeptin) at 9,000 rpm for 10 seconds using a mechanical homogenizer (IKA-T25 digital
Ultra-Turrax) with ice-cold probe. The size of myofibrils was checked under a phase contrast
microscope (objective lens: 40x Plan, Ph2, Olympus BX40). The homogenate was centrifuged at
2,500x g, 4˚C for 5 minutes. The pellet was re-suspended in five volumes of washing solution (60
mM KCl, 30 mM imidizole, pH7.0, 2 mM MgCl2, 1 mM DTT, 1 µg/mL Leupeptin and 0.5% (v/v)
Triton X-100) and centrifuged at 2,500x g for 5 minutes. Three more washes were repeated using
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the same washing solution except without Triton X100 in the buffer.

Prior to the final

centrifugation, the suspension was filtered through a 100µm nylon mesh. Myofibrils were used
within a few days on ice or stored at -20°C in 50% glycerol. The protein concentration of the
myofibril preparations were estimated from the absorption value of the lysate at wave length
280 nm using the extinction coefficient 7.0 after dissolving the myofibril solution in sodium
dodecyl sulfate. The myosin concentration in the preparations was then determined by assuming
that half of the myofibrillar proteins are myosin II.
5.3 ATPASE ASSAY
The steady state ATPase activities of WT and cTnI-ND myofibrils were measured using
NADH-coupled ATP-regenerating system in the MB50 buffer containing 20 mM MOPS pH 7.0, 5
mM MgCl2, 2 mM ATP, 100 mM KCl, 1 mM ATP, 200 µM NADH, 1 mM phosphoenolpyruvate, 200
U/ml pyruvate kinase, 40 U/ml 1-lactic dehydrogenase and various concentrations of calcium
(pCa ranging from 9 to 3)53. Myofibrils prepared from WT and cTnI-ND hearts (n=5 for each) were
used to measure the steady state ATPase. The experiments were performed at different days.
The free calcium concentration was calculated using the method described by Fabiato54. The
reactions were initiated by the addition of 1 mM ATP and the change in the absorbance at 340
nm resulted from NADH oxidation was monitored with a spectrophotometer (Cary50, Agilent).
NADH’s extinction coefficient (ε) of 6220 M-1cm-1 was used to calculate the Mg-ATPase activity.
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5.4 STOPPED FLOW METHOD
5.4.1 TECHNIQUE
Stopped-flow spectroscopy (Fig. 6) is a common rapid kinetics technique used for
studying fast reaction mechanisms in solution over timescales of about 1ms up to 100’s seconds.
In general, a single mixing stopped flow system rapidly mixes two reagents together and then
passes the solution into an observation cell where the flow is then stopped. A double mixing
stopped-flow system is capable of
mixing three reactants in sequential
fashion to perform double mixing
experiments. In this more complex
system there are three drive
syringes.
The first two drive syringes
Figure 6. Stopped-flow configuration. Small volumes of reactants
are rapidly driven from the syringes into a mixer to initiate a
reaction. The resultant reaction volume then displaces the inject two solutions together
contents of an observation cell and fills it with freshly mixed
reagents.
through a mixer and into a delay
line. The length of the delay line along with how long it takes the solutions to pass through the
delay line determines the length of the first reaction. After passing through the delay line the first
two solutions, that are now mixed, enter a second mixer where they are mixed with a third
reactant and then the mixed solutions pass into the flow cell. The reactants displace the previous
contents of the observation cell. In both cases, when the flow is stopped, the sample cell is
irradiated with monochromatic light and as the reaction proceeds the change in the recorded
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fluorescence signal is recorded as a function of time. Analysis of the resulting kinetic transient
allows us to determine kinetics of the reaction, or more specifically, the reaction rate.
Regardless of which configuration the stopped- flow uses, the time resolution of this
method is limited by the time required for the reactants to flow from the last mixer to the
observation cell. This time is referred to as the dead time of the instrument.
5.4.2 FLUORESCENT PROBES
In order to measure a specific reaction, a particular fluorophore needs to be chosen. In
this study, we use the fluorescent analogue of adenosine triphosphate (ATP) and (ADP) known as
2'- / 3'- O- (N'- Methylanthraniloyl)adenosine- 5'- O- triphosphate (mant-ATP) and 2'- / 3'- O- (NMethylanthraniloyl)adenosine- 5'- O- diphosphate (mant-ADP), respectively. By using these
fluorescent probes, we can monitor the ATP/ADP binding or dissociation events of myosin via
Förster energy transfer (FRET).
5.4.3 MEASUREMENTS OF SOLUTION TRANSIENT KINETICS
All the transient kinetic measurements of myosin intrinsic tryptophan fluorescence were
performed with a stopped flow apparatus (SFM-300, Biologic USA) using a micro-cuvette (μSf-8,
cuvette volume = 4 μl) operated by the provided software (Bio-kine, Bio-logic USA) in the buffer
containing 20 mM MOPS pH 7.0, 5 mM MgCl2, 2 mM ATP, 100 mM KCl with various
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concentrations of Ca2+. The
experimental

temperature

(23°C) was controlled by a
water-chiller system (endocal
RET series, Neslab). The deadtimes were 0.25 msec for a total
flow-rate of 13.3 ml/s and 1
msec for a total flow-rate of 4
ml/s. Mant-dATP and mantdADP were excited at 280 nm
wavelength
resonance

via
energy

Förster
transfer

(FRET) from an intrinsically
conserved tryptophan residue

FIGURE 7. Myofilament protein composition and steady state ATPase
activities of myofibrils isolated from cTnI-ND transgenic and WT mouse
hearts. (A) Top-panel: The SDS-PAGE gel shows the preserved
myofilament protein composition in myofibrils isolated from frozen WT
and cTnI-ND transgenic mouse hearts in comparison with that of fresh
intact cardiac muscle. Bottom-panel: Western blot using anti-TnI
monoclonal antibody TnI-1 confirmed the presence of solely cTnI-ND in
the cTnI-ND transgenic hearts and myofibrils. MHC: myosin heavy chain.
(B) ATPase activity of cTnI-ND (n = 5 mice, open red; frozen heart and n =
4 mice, closed black; non-frozen heart) and WT (n = 5 mice, open black
circle; frozen heart and n = 4 closed blue; non-frozen heart) cardiac
myofibrils in the absence of and the presence of various calcium
concentrations (pCa) at 23 °C. The pCa50 values of myofibril for frozen and
non-frozen hearts were 5.32 ± 0.12, 5.21 ± 0.13 for cTnI-ND and 6.29 ±
0.08, 6.25 ± 0.15 for WT, respectively (p < 0.01, in Student’s t test for
ATPase rate between cTnI-ND and WT at pCa 6).

(Trp509) within the cardiac myosin II motor domain. The emitted light was selected using a 400
nm long pass filter and the fluorescence signal was acquired at 90° from the excitation path.
The fitting of experimental data to the time course was done using software provided by
Bio-logic USA (Bio-kine) and Origin Pro Ver 8.5 (Origin lab). Each data point (i.e., at a given pCa
and a given nucleotide concentration) was averaged over 4 ~ 6 traces and was fitted to single (Eq.
1 for less than 25 µM nucleotide) or double (Eq. 2 for nucleotide concentrations ≥ 50 µM)
exponential equation as follows:
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I(t) = I0exp(-kFastt) + C

(Eq. 1)

I(t) = I1exp(-kFastt)+I2exp(-kSlowt) + C

(Eq. 2)
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FIGURE 8. Measurements of the sarcomere length and width of myofibrils purified from frozen and
non-frozen (fresh) cTnI-ND and WT hearts at 23˚C. (A, B, D, E, J, K, M, and N) DIC (top) and fluorescence
images (bottom) of myofibrils were taken and the line scan data (yellow line in bottom of B, E, K, and N)
were analyzed with a sum of Gaussian function (C, F, L, and O). Distance between the peaks was
calculated and plotted in a histogram (G, H, P, and Q). The sarcomere lengths of all data were
summarized in Supplemental Table 1. The thickness (width) of myofibrils was measured by the line scan.
The intensity profile of the myofibrils was plotted in I and R. The data were fitted with a single Gaussian
function. The width of the myofibrils was represented as mean ± standard deviation
(S.D.).
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I(t) is the fluorescence signal over the time t, kFast and kSlow are the apparent rates. I0, I1, and I2 are
the corresponding amplitude coefficients of the fast and slow exponential parts.
5.4.4 STATISTICAL ANALYSIS
All data are presented as mean ± SD, and n refers to the number of mouse hearts studied.
Statistical analysis for the difference between the cTnI-ND and WT groups was performed using
paired two-tailed student’s t-test and significance is reported as p > 0.05 and p < 0.01.
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CHAPTER 6 EFFECTS OF THE NH2-TERMINUS OF CTNI
6.1 RESULTS
6.1.1 PREPARATION OF INTACT CARDIAC MYOFIBRILS FROM FROZEN ADULT MOUSE HEARTS
To assess the integrity of the Triton X-100 skinned myofibrils, the protein extracts from
intact heart tissues and skinned myofibrils were analyzed by SDS-PAGE and Western blots. As
shown in Figure 7A, SDS-PAGE revealed that the representative myofibrillar proteins such as
myosin heavy chain, actin, cTnI or cTnI-ND were well preserved in the isolated myofibrils.
Quantitative densitometry of SDS-PAGE gels found no significant difference of myosin and actin
between the total cardiac muscle homogenate and isolated myofibrils (data not shown).
Immunoblot analysis using anti-TnI monoclonal antibody TnI-1 confirmed the sole presence of
cTnI-ND in the transgenic mouse cardiac myofibrils and the absence of intact cTnI (Fig. 7A,
bottom). The data demonstrated the effectiveness of preparing adult cardiac myofibrils from
frozen mouse hearts for functional studies.
To demonstrate that the purified myofibrils preserved sarcomeric structure, myofibrils
from frozen and fresh hearts were labeled with rhodamine phalloidin and imaged by using a
confocal microscope (Fig. 8) in the presence and absence of ATP and without calcium.
Fluorescence images were used to measure the intensity of the position of the thin filament by
line-scan (Fig. 8, red). The intensities were then analyzed by the sum of Gaussian function (Fig. 8
C, F, L, and O). The distance between peaks was calculated and plotted as a histogram (Fig. 8 G,
H, P, and Q), which was fit with a single Gaussian function (Fig. 8 G, H, P, and Q). The slack
sarcomere lengths of cTnI-ND and WT with and without ATP were not significantly different (~1.8
µm) under all conditions (Table 1). Thickness (width) of myofibrils was measured by DIC images
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with the line scan method. The parameters obtained from all groups were not significantly
different (1.1 ~ 1.3 µm, Table 1). No shortening of myofibrils was found.
6.1.2 CTNI-ND RESULTS IN DECREASED SENSITIVITY OF CARDIAC MYOFIBRIL ACTOMYOSIN
ATPASE TO CALCIUM ACTIVATION
The steady-state ATPase activity of myofibrils prepared from frozen and fresh hearts of
cTnI-ND and WT mice was measured under different Ca2+ concentrations (pCa 3-9). For frozen
heart experiments, the maximal ATPase rate (Vmax) of cTnI-ND myofibrils (red open circle, 10.1
± 0.42 s-1) (< pCa4) was slightly lower than that of WT (open circle, 12.7 ± 0.77 s-1). The ATPase
rates of WT and cTnI-ND at pCa 9 were 0.36 ± 0.12 and 0.29 ± 0.09 (s-1), respectively. The pCa50s
of ATPase activation for frozen heart were 5.32 ± 0.12 for cTnI-ND and 6.29 ± 0.08 for WT
myofibrils, respectively (p < 0.01 for comparing the rates of 50% maximum ATPase, Fig. 7B),
demonstrating a lower calcium sensitivity of the cTnI-ND myofibrils as compared with that of WT
myofibrils. The steady state ATPase activity of myofibrils from fresh (non-frozen) mouse hearts
(cTnI-ND: black circle, WT: blue circle) further validated the use of frozen heart for reliable
kinetics studies (Fig. 7B).
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Table 1: Sarcomere length and thickness (width) of myofibrils
Genotype ATP
Frozen Heart
Non-frozen (Fresh) Heart

cTnI-ND

SL: 1.89 ± 0.34 µm (n: 75)
Width: 1.22 ± 0.10 µm (n: 23)

SL: 1.85 ± 0.34 µm (n: 75)
Width: 1.12 ± 0.12 µm (n: 24)

SL: 1.89 ± 0.37 µm (n: 85)
Width: 0.98 ± 0.12 µm (n: 28)

SL: 1.99 ± 0.36 µm (n: 88)
Width: 1.03 ± 0.13 µm (n: 27)

-ATP

+ATP

WT

SL: 1.92 ± 0.39 µm (n: 69)

SL: 1.92 ± 0.41 µm (n: 85)

Width: 1.01 ± 0.10 µm (n: 21)

Width: 0.98 ± 0.13 µm (n: 26)

SL: 1.90 ± 0.30 µm (n: 68)
Width: 1.12 ± 0.09 µm (n: 20)

SL: 1.99 ± 0.45 µm (n: 93)
Width: 1.32 ± 0.13 µm (n: 28)

-ATP

+ATP
SL: Sarcomere length. The data are means ± S. D. (e.g. S.D. is standard deviation). Three heart
sets were used. n: total number of data points, not heart number.
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6.1.3 N-TERMINAL EXTENSION OF CTNI AFFECTS CALCIUM RESPONSE OF THE INITIAL
ACTOMYOSIN-ATP COMPLEX FORMATION

Figure 9. Fluorescence traces of mant-dATP
binding to cardiac myosin in cTnI-ND and WT
myofibrils. Isolated myofibrils were mixed with
various concentrations of mant-dATP at different
Ca2+ concentrations (pCa 9, 6, and 3). Binding
events were monitored by FRET signal via
intrinsically conserved tryptophan 509 to
mantdATP at 23 °C (see Materials and Methods). (A
– C) Normalized typical traces of mant-dATP
binding for cTnI-ND myofibrils (D-F) and for WT
myofibrils (D –F) at pCa 6. Note that the maximum
signal from at 800 µM mant-dATP was used to
normalize all data. Three different mant-dATP
concentrations (5 µM for A and B, 50 µM for B and
E, and 500 µM for C and F) are shown. The data
were fit with single exponential function for A (r2 =
0.952) and D (r2 = 0.861) and double exponential
function for B (r2 = 0.863), C (r2 = 0.901), E (r2 =
0.855), and F (r2 = 0.851). at pCa 6. All conditions
used four hearts of cTnI-ND (n = 4) and WT (n = 4).
Three to four traces at each data point were
averaged. The averaged data from three to four
heart-sets was calculated as mean ± S.D. All insets
in A – F are short time scales (100 msec).

To evaluate the ATP-binding rates, skinned myofibrils were mixed with various amounts
of mant-dATP at different Ca2+ concentrations (pCa 9, 6, and 3) and the fluorescence intensity
was monitored over time (Figure 9). The fast and slow phases of mant-dATP binding rates
calculated from the fluorescence traces in Figure 9 were plotted against mant-dATP
concentrations under various pCa (Figure 10 and Table 2).
After the flow was stopped at 4 msec in Fig. 9B and 9C, the increasing fluorescence signals
were analyzed. To confirm whether the increasing signals were ATP binding events, we examined
the same experiment in the absence of myofibrils, the absence of mant-dATP, and the absence
of both mant-dATP and myofibrils (data not shown). In the absence of myofibrils, the signals did
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not increase at all mant-dATP concentrations after stopped flow, indicating that the changes
were solely from mant-dATP binding to myosin. Note that the changing of mantdATP signal was
detected before the syringe stopped. Thus, the signal at the point of stopping syringe is
proportional to mant-dATP concentration. In the absence of mant-dATP or/and myofibrils, the
fluorescence signals before and after syringe stop were not changed, meaning that the
fluorescence signal from tryptophan or mant-dATP itself did not leak out from the emission filter
(long pass filter from 400 nm). Recent studies showed that the rate of kinetics was detected by a
conformational change at the Trp residue when ATP binds to myosin. To confirm that our data
after the flow stopped did not include the Trp signal, myofibril suspension and 1 mM ATP were
mixed and monitored (data not shown). The fluorescent signal from Trp was not detected before
and after stopped flow. This shows that the 400 nm long pass filter cut out the Trp signal. Further
confirming that the increased signal after the stopped flow resulted from the mant-dATP binding
events. The fast and slow phases for all ATP concentrations were plotted in Fig. 10. In Fig. 10 AC, the data were fitted by Michaelis-Menten. The K1 (mM-1) is calculated by 1/Km (Km (mM), which
is the [ATP] at the half maximum rate), and k2’ is the maximum rate.
During the fast phase of ATP-binding, we found that K1 (µM-1), which is the equilibrium
constant for the formation of the initial actomyosin-ATP complex in the myosin ATPase kinetic
cycle (Scheme 1), was increased by three folds in WT myofibrils when pCa was increased from 9
to 6. However, cTnI-ND myofibrils showed highest K1 in pCa 9 without change with the increases
in pCa (Table 2).
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k2’ (s-1), which represents the myosin head isomerization step where there is maximum
binding to myosin (Scheme 1), in both cTnI-ND and WT myofibrils was not significantly affected
by calcium concentration (Figure 8A - C and Table 1). However, k2 (s-1) was constantly higher in
cTnI-ND myofibrils than that of WT under all pCa conditions examined.
K1k2’ (µM-1s-1), which is the second order-rate constant of mant-dATP binding and
represents the initial slope at low concentration of mant-dATP (< 20 µM) (Scheme 1), of cTnIND
myofibrils was ~3.4 fold as fast as that of WT myofibrils at pCa 9 (p < 0.01). The difference in K1k2’
(µM-1s-1) between cTnI-ND and WT myofibrils was diminished when Ca2+ concentration was
increased (Table 1 and Fig. 10 D – F, p < 0.01 for pCa 3 vs. pCa 9 and p < 0.01 for pCa 3 vs. pCa 6).
An ~ 2.5 fold higher K1k2’ was observed in WT myofibrils at pCa6 than that at pCa 3 and 9 (both p
< 0.01; pCa 3 vs. pCa 6 and pCa 6 vs. pCa 9), which was not seen in cTnI-ND myofibrils.
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In contrast to the fast ATP-binding rates, the slow rates of ATP binding obtained from the
double exponential fitting at higher concentrations of mant-dATP (>50 µM) were not significantly
different between cTnI-ND and WT myofibrils under the Ca2+ concentration examined (Fig. 10 G
– I). The slow rates were independent of mant-dATP concentration and were around 25 ~ 40 s-1.
The amplitudes of fast and slow rates of the total intensity after stopped syringes were 86% and
14%, respectively, and were independent of ATP concentrations.
Although it is difficult to interpret this result in contrast to that in purified actomyosin-S1
experiments, recent studies suggested that a slow rate step in such experimental setting should
be the hydrolysis of ATP hydrolysis (k3+k-3) 55. Actomyosin S1 studies found that the ATP cleavage
rate (k3+k-3) is about 10-30% of k2’ 56. Thus, our slow mantdATP binding rate may indicate the ATP
hydrolysis rate.
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Figure 10. Fast and slow phases of mant-dATP binding rate of cardiac myosin. (A – C) The analysis of the
fast rate obtained from the fluorescence traces of mant-dATP binding for cTnI-ND (n = 4 hearts, closed
circle) and WT (n = 4 hearts, open circle) myofibrils against different ATP concentrations at different Ca 2+
concentrations (A pCa 9; B, pCa 6; and C, pCa 3). Data were fitted by a hyperbola. (D – F) The second order
rate constant (K1k2) of mant-dATP binding to myosin in the myofibrils was calculated at lower mant-dATP
concentration (< 20 µM). The p value for comparing the K1k2 rates between cTnI-ND and WT myofibrils
were: D, p < 0.01; E, p < 0.05; F, p > 0.07. Data are fitted with a linear regression. (G – I) The slow phase of
mant-dATP binding rates. The rates for cTnI-ND (open circle) and WT (closed circle) myofibrils were
measured at three different pCa (9, 6, and 3). Solid lines (cTnI-ND) and dot lines (WT) are the average of all
data sets. Data represent means ± S.D.
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6.1.4 CTNI-ND DECREASES THE RATE OF MANT-DADP DISSOCIATION
We next measured the rates of mant-dADP dissociation from myosin II of the cTnI-ND and
WT cardiac myofibrils at various Ca2+ concentrations (pCa 9 through 3) using a double-

Figure 11. Fluorescence traces of mant-dADP dissociation at different calcium concentrations. (A)
Schematics of double-mixing experiment. 1 µM myofibril and 2 µM mant-dADP were mixed and incubated
for 20 sec in a delay line (yellow rectangle) and then the solution was mixed with 1 mM ADP. Three
fluorescence traces with different calcium concentrations (pCa: 9, 6, and 3, respectively) were shown. (B –
D) cTnI-ND myofibrils (n = 4 hearts); (E – G) WT myofibrils (n = 4 hearts). Red solid lines are fitting curves
with double-exponential equation. (H) Fast phase of mant-dADP dissociation rates in cTnI-ND (closed circle)
and WT (open circle) myofibrils. Data were fitted with non-linear least-squares regression.
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mixing method by the addition of excess ADP (1 mM) to a pre-mixed solution containing 2 µM
mant-dADP and 1 µM myofibrils (Figure 11 A). The fluorescence intensity decreased over time
due to mant-dADP dissociation from cardiac myosin II (Figure 11 B - G).
At pCa 9, the fast phase of mant-dADP dissociation rate in cTnI-ND myofibril was 250 ± 36
s-1, much lower than that of WT myofibrils (396 s-1, p < 0.01). However, the dissociation rate of
mant-dADP in cTnI-ND myofibrils was increased to 386 ± 429 s-1 when increasing the Ca2+
concentration to pCa 3 (p < 0.01, as compared the rates between pCa 9 and 3, Figure 8 H and
Table 2). By contrast, the dissociation rate of mant-dADP in WT myofibrils was not significantly
different between pCa 9 and pCa 3 (p > 0.05, Figure 11 H and Table 2).
These results indicates that the amount of myosin motor domain in cTnI-ND myofibrils
bound to the thin filament was less than that in WT myofibrils at lower concentration of Ca 2+, a
condition, at which WT myofibrils were already exhibited maximal binding capacity (see
Discussion).
6.1.5 CTNI-ND DECREASES THE RATE OF ADP DISSOCIATION
We also examined the dissociation of ADP from myofibril actomyosin under various Ca 2+
concentrations (pCa 9 through 3) using mant-dADP chasing method in which excess mant-dATP
(800 µM) was added to the premixed solution containing 1 µM myofibril and 2 µM ADP (Figure
12). The increased fluorescence signal induced by mant-dATP binding to myosin was fitted to a
double exponential equation (Eq. 2, Figure 12 B - G) and the corresponding fast phase ADP
dissociation rate constants were determined (Figure 12H and Table 2).
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Figure 12. Representative traces of ADP dissociation by mant-dADP-chasing for cTnI-ND and WT myofibrils. (A)
Schematics of double-mixing experiments. In double mixing reaction, 1 µM myofibril and 2 µM ADP were mixed
and incubated for 20 sec in a delay line and then the solution was mixed with 800 µM mant-dADP. (B – D) cTnIND myofibrils (n = 4 hearts). (E – G) WT myofibrils (n = 4 hearts). Red solid lines are fitting curves with single or
double exponential equation. (H) Fast phase of ADP dissociation rates in cTnI-ND (closed circle) and WT (open
circle) myofibrils at different calcium concentrations (pCa). Data were fitted with non-linear least-squares
regression (solid and dashed lines). Asterisks indicate statistical significances in Student’s t test. *p < 0.01 of cTnIND myofibrils for comparing the rates between pCa 3 and pCa 9. **p > 0.05 WT myofibrils for comparing the
rates between pCa 3 and pCa 9. Data represent means ± S.D.
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Consistent with the results in Figure 11, the ADP dissociation rate of cTnI-ND myofibrils
was lower than that of WT myofibrils at pCa9 (290 ± 41 s-1 for cTnI-ND vs. 426± 38 for WT, p<
0.01), but was dramatically increased when increasing Ca2+ concentration to pCa 3 (499 ± 39 s-1,
p < 0.001 for comparing the rates between pCa 9 and pCa 3), while the rate of WT myofibrils was
not significantly affected by the change of concentrations.
6.1.6 CTNI-ND DID NOT AFFECT THE RATES OF THE SLOW PHASE OF MANT-DADP AND ADP
DISSOCIATION
The rates for the slow phase of mant-dADP and ADP dissociation were calculated from
data shown in Figure 11 and Figure 12, respectively (Figure 13). The rates were not significantly
different between the cTnI-ND and WT myofibrils under all Ca2+ concentrations tested and both
were slightly decreased when Ca2+ concentration was increased (Figure 13 A and B). The
amplitude of the slow phase dissociation was less than 5% of the total amplitude of the
fluorescence intensity, suggesting that the slow phase is a small fraction of exchange between
ADP binding and dissociation.
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Figure 13. Slow phase of mant-dADP and ADP dissociation rates for cTnI-ND (closed circle) and WT
(open circle) myofibrils against different Ca2+ concentrations. Data for cTnI-ND (solid line) and WT
(dashed line) myofibrils were fitted with non-linear least-squares regression. Data represent means ±
S.D.

6.2 DISCUSSION
6.2.1 ASSESSING ATPASE ACTIVITY WITH SKINNED MYOFIBRILS
cTnI differs from the fast and slow skeletal muscle TnI mainly by the N-terminal
extension57,58. The embryonic heart expresses solely slow skeletal muscle TnI that ceases
expression during postnatal development while cTnI up-regulates to become the sole TnI in adult
hearts58. Therefore, the N-terminal extension of cTnI is an adult heart-specific regulatory
structure.
To investigate the mechanistic basis for the regulatory function of the N-terminal
extension of cTnI, we studied the ATPase kinetics of myofibrils isolated from cTnI-ND and WT
mouse hearts. ATPase assay at various calcium concentrations showed that cTnI-ND myofibrils
at pCa 6 have lower calcium sensitivity than the WT controls (∆pCa: 0.34). Previous studies
showed that the N-terminal truncated cTnI mimics the effect of phosphorylation or
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pseudophosphorylation mutations of Ser23/24 on decreasing the calcium affinity of troponin,
resulting in faster relaxation of cardiac muscle59,30,34,31,60. Our results obtained from skinned
myofibrils isolated from frozen cardiac muscle are consistent with the previous data, validating
the experimental system used in this study. Function of the N-terminal extension of cTnI in
regulating the relaxation velocity of cardiac muscle30,28 suggests a role in modulating the
interaction between myosin and thin filament. The decreased sensitivity of the myofibrils may
be obstructive for the activation of actomyosin ATPase. In this hypothesis, decreased binding of
myosin to actin filament would result in slower ATPase rates since the ATPase rate of myosin
alone is 100 times slower than that of actomyosin. Thus we hypothesized that the N-terminal of
cTnI modulates the interaction between actomyosin. In fact, the sensitivity of calcium of cTnIND
myofibrils in ATPase is lower than that of WT myofibrils.
The data that myofibrils prepared from snap frozen mouse hearts could be effectively
used in the transient kinetics studies to quantitatively measure the ATP binding and ADP
dissociation rates significantly facilitates the application of long term stored muscle tissues for
functional investigations.
A previous rapid quench-flow experiment showed that the ATPase of myofibrils was 50 to
100 times activated by calcium61. Our myofibril ATPase assay was measured over second and
showed about 35-fold increase from pCa 9 to 3. This slightly lower activation may be due to the
fact that the high calcium concentration at pCa 3 caused myofibrils to over contract and not to
be able to produce optimal activity.
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6.2.2 THE N-TERMINAL EXTENSION OF CTNI DOES NOT AFFECT ATP BINDING TO CARDIAC
MYOSIN II
Myofibril ATPase assay at differenet calcium concentrations was measured and activated
10-fold from pCa 9 to pCa 3. Mant-dATP binding rate from pCa 9 and pCa 3 did not show such
large difference. Thus, we conclude that mant-dATP binding was not significantly affected by
calcium concentration.
To further understand the mant-dATP binding events, absolute initial intensity signals and
absolute fluorescence changes were analyzed (data not shown). When the flow was stopped, the
fluorescence signal of mant-dATP with myofibrils can be measured at the initial fluorescence
signal. However, some mant-dATP fluorescence signal leaked from the 400 nm long pass filter
and the initial intensity is proportional to the increasing mant-dATP concentration. Thus, the
initial fluorescence signal was subtracted by mant-dATP fluorescence signal alone as an absolute
initial signal. The absolute initial intensity of both cTnI-ND and WT myofibrils is proportional to
the increase in mant-dATP concentration and saturated after 300 µM. The absolute initial
intensity of cTnI-ND showed no change over the pCa range, while that of WT is slightly increased.
This result suggests that mant-dATP easily binds to myosin in cTnIND myofibrils more than that
of WT and that WT myofibrils has a little sensitivity of mant-dATP binding for calcium
concentration.
The absolute fluorescence change is the total fluorescence signal change after the flow
was stopped. The absolute fluorescence changes of cTnI-ND at pCa 9 and 6 are similar for all
mant-dATP concentrations, but the absolute fluorescence change at pCa 3 increased more at
higher mant-dATP concentrations. This result shows similar behavior to the results of the ATPase
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assay, but there was not enough difference between pCa 6 and pCa 3 ATPase rates. The plots of
the absolute fluorescence change for WT myofibrils were similar in manner at all pCa. These
results showed a little calcium sensitivity for cTnI-ND myofibril signals.
The ratio between absolute fluorescence change and absolute initial intensity was plotted
against pCa. The ratio for both cTnI-ND and WT myofibrils is low at high mant-dATP
concentrations, suggesting that most myosin in the myofibrils bind to mant-dATP. cTnI-ND and
WT myofibrils were not significantly different at pCa 3 and 6. cTnI-ND myofibrils exhibited a
significantly higher ratio at pCa 9 than that of WT. This means that some myosin in cTnI-ND
myofibrils easily bind to mant-dATP compared to that of WT. Thus, K1k2’ of cTnI-ND may be
higher than that of WT. However, this is difficult to interpret as long as it is unclear of the number
of actomyosin cross-links at these calcium concentrations.
6.2.3 N-TERMINAL EXTENSION OF CTNI MODLATES CALCIUM-DEPENDENT ADP DISSOCIATION
We employed double-mixing stopped flow methods to investigate the effect of the Nterminal truncated cTnI on ADP dissociation from cardiac myosin in WT and cTnI-ND myofibrils
from pCa 9 to pCa 3. Together with the mant-dADP chasing results in Fig 12, the amplitudes of
the slow rates were independent of pCa and were ~5% of total signal after the syringes stopped.
Thus, we conclude that the data represent true ADP dissociation events.
Our results in Fig. 11, Fig. 12, and Table 3 showed that the fast rates of ADP and mantdADP
dissociation from cTnI-ND myofibrils are calcium dependent, whereas the rates of WT myofibrils
are faster and did not significantly change over calcium concentrations. Previous studies have
shown that the ADP dissociation rate from actomyosin is ~100-fold faster than that from myosin
alone, meaning that thin filament binding to myosin accelerates ADP dissociation 56, 62-65. Thus,
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the ADP dissociation rate depends on the number of cross-bridges of actomyosin. Our results
suggest that at low calcium concentrations corresponding to that in a relaxed cardiomyocyte,
myosin heads in cTnI-ND myofibrils may bind less to the thin filament than that in WT myofibrils.
The rate-limiting step in actomyosin ATPase cycle can be changed by tension in the
myofilaments, due to transitions from weak to strongly bound cross-bridges66. For isometric
contraction of muscles, the ADP release step is rate-limiting step, whereas in shortening and
force reducing contractile muscle fibers, the Pi release is rate-limiting step. Recently, an attached
and detached pathway model 67 was proposed to explain muscle contraction, which was based
on the Geeves and Holmes model 68-70. The Lionne and Barman model suggests that Pi release in
myofibrils is the rate-limiting step because of the reduced force in the myofibrils, 67, 71, in which
myofibrils represents a system of “attached pathway”. In cTnI-ND myofibrils myosin may bind
the thin filament less than that in WT myofibrils at pCa 6 due to the lower calcium sensitivity of
troponin, resulting less myosin heads bound to the thin filaments and the accumulated AM·ADPPi state. To test this hypothesis, phosphate release measurements are needed in future studies.
Based on the experiments using native mouse cardiac myofibrils in the presence of
physiologically integrated myofilaments, our present study demonstrated that the N-terminal
extension of cTnI plays a role in regulating the actomyosin ATPase cycle of the cardiac muscle.
More studies are needed to fully understand how the restrictive proteolysis regulation of the
adult heart-specific N-terminal extension of cTnI

72-74

functions in the calcium activation and

kinetics of each step of the cardiac myosin II ATPase cycle. Although our data showed that the
ATP binding rates and ADP dissociation rates did not have large contributions to the calcium
regulation of ATPase in isolated myofibrils due to the unloaded condition, the slower and calcium
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dependent fast rates of ADP dissociation from cTnI-ND myofibrils (Fig. 11, Fig. 12, and Table 3),
implicate a function of the N-terminal extension of cTnI in regulating the relaxation of cardiac
muscle as that observed in ejecting working hearts 72, 73. Therefore, the rate limiting effect of the
phosphate release step 67 merits further investigation.
6.3 CONCLUSION
Based on the experiments using native mouse cardiac myofibrils in the presence of
physiologically integrated myofilament proteins, our present study demonstrated a novel role of
the N-terminal extension of cTnI in regulating the actomyosin ATPase cycle of cardiac muscle.
More studies are merited to fully understand how the restrictive proteolytic regulation of the
heart-specific N-terminal extension of cTnI30,27,28 functions in the calcium activation and the
kinetics of each step of the cardiac myosin II ATPase cycle.
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CHAPTER 7 THE EFFECTS OF THE NH2-TERMINUS OF CTNT
While cTnI undergoes a restrictive proteolytic truncation of the NH2-terminal extension
in normal hearts and is upregulated in cardiac adaptation to hemodynamic stress or β-adrenergic
deficiency to increase the rate of relaxation, another subunit of the troponin complex also
undergoes a truncation during myocardial ischaemia reperfusion. The cTnT NH2terminal
extension also undergoes a restricted cleavage that decreases the rate of contraction. Thus, it is
important to understand the mechanistic basis of this truncation in order to understand and treat
heart failure.
7.1 STOPPED-FLOW EXPERIMENTS
All stopped-flow measurements were performed as described in Chapter 5, at 20 °C using
an SFM-300 stopped-flow apparatus (Biologic USA, Knoxville, TN) fit with three 2 mL syringes, a
micro-cuvette (µSf-8, cuvette volume = 4 µl) and a dead time of 1 msec for a total flow-rate of 4
ml/s. In double-mixing experiments, myofibrils and nucleotide or nucleotide analog were mixed,
allowed to incubate for the desired time, and then mixed with nucleotide, producing a 1/3 dilution
of all constituents in the flow cell. Single-mixing experiments produced a 2/3 dilution of myofibrils
and 1/3 dilution of nucleotide in the flow cell. Mant-dATP and mant-dADP were excited at 280
nm wavelength via Förster resonance energy transfer (FRET) from an intrinsic tryptophan residue
(Trp509) in the motor domain of cardiac myosin II. The emitted light was selected using a 400 nm
long pass filter, and the fluorescence signal was acquired at 90° from the excitation path.
Experimental data fitting was completed using softwares provided by Bio-logic USA
(Biokine) and Origin Pro Ver 8.5 (Origin lab, Northampton, MA). Each data point at a given pCa
and a given nucleotide concentration was averaged over 3 ~ 5 traces and was fitted to single (Eq.
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1 for less than 50 µM nucleotide) or double (Eq. 2 for nucleotide concentrations ≥ 50 µM)
exponential equation for mant-dATP binding experiments and double exponential equation for
ADP and mant-dADP dissociation experiment as follows:
I(t) = I0exp(-kFastt) + C

(Eq. 1)

I(t) = I1exp(-kFastt)+I2exp(-kSlowt) + C (Eq. 2)
where I(t) is the fluorescence signal over the time t, and kFast and kSlow are the apparent rates. I0,
I1, and I2 are the corresponding amplitude coefficients of the fast and slow exponential parts.
The fitting goodness was evaluated by the r2 value in order to determine whether the data can
be fitted by single or double exponential.
7.2 RESULTS
7.2.1 PREPARATION OF INTACT CARDIAC MYOFIBRILS FROM FROZEN ADULT MOUSE HEARTS
To assess the integrity of the Triton X-100 skinned myofibrils, the protein extracts from
intact heart tissues and skinned myofibrils were analyzed by SDS-PAGE and Western blots. As
shown in Figure 14A, SDS-PAGE revealed that the representative myofibrillar proteins such as
myosin heavy chain, actin, cTnT or cTnT-ND were well preserved in the isolated myofibrils.
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Quantitative densitometry of SDS-PAGE gels found no significant difference of myosin
and actin between the total cardiac muscle homogenate and isolated myofibrils (data not
shown).
analysis

Immunoblot
using

anti-TnT

monoclonal antibody CT3
confirmed the presence of
cTnT-ND in the transgenic
mouse cardiac myofibrils
(Fig. 14A, bottom). Note that
WT expressed some cTnTFigure 14 Myofilament protein composition and steady state ATPase activities

ND, which is possibly due to of myofibrils isolated from cTnT-ND transgenic and WT mouse hearts. (A) Topthe

preparation

myofibrils,

of

the

however

the

level of cTnT-ND in WT
myofibrils is still lower than
that

in

the

transgenic

panel: The SDS-PAGE gel shows the preserved myofilament protein composition
in myofibrils isolated from frozen WT and cTnT-ND transgenic mouse hearts in
comparison with that of fresh intact cardiac muscle. Bottom-panel: Western
blot using anti-TnT monoclonal antibody CT3 confirmed the presence of cTnTND in the cTnI-ND transgenic hearts and myofibrils. MHC: myosin heavy chain.
(B) ATPase activity of cTnT-ND (n = 3 mice, closed red) and WT (n = 4 mice,
closed black circle) cardiac myofibrils in the absence of and the presence of
various calcium concentrations (pCa) at 23 °C. The pCa50 values of myofibrils
from cTnT-ND and WT hearts are 4.66±0.02 and 4.67±0.01, respectively.
*p<0.05 for comparing the maximum ATPase rate between WT and cTnT-ND at
pCa 3.

myofibrils. The percentage of cTnT and cTnT-ND of the total cTnTs are 68.60% and 31.40% in
WT and 31.99% and 68.01% in the cTnT-ND heart. The data demonstrated the effectiveness
of preparing adult cardiac myofibrils from frozen mouse hearts for functional studies.
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7.2.2 CTNT N-TERMINAL TRUNCATION DOES NOT AFFECT THE CALCIUM SENSITIVITY OF
MYOFIBRILAR ATPASE
The steady-state ATPase activity of myofibrils prepared from frozen hearts of cTnT-ND
and WT mice was measured under different Ca2+ concentrations (pCa 3-9)(Figure 14) . For ATPase
experiments, the maximal ATPase rate (Vmax) of cTnT-ND myofibrils (11.51±1.56 s-1) (< pCa4) was
significantly lower than that of WT (19.75±2.99 s-1), with p=0.04975. The pCa50s of ATPase
activation for frozen heart were 4.66 ± 0.02 and for cTnI-ND and 4.67 ± 0.01 for WT myofibrils,
demonstrating no change in calcium sensitivity of the cTnT-ND myofibrils as compared with that
of WT myofibrils.
7.2.3 MANT-DATP BINDING
Mant-dATP binding was measured by monitoring the enhancement of the FRET signal that
arises when mant-dATP binds to myosin II motor domain. To evaluate the ATP-binding rates,
myofibrils were mixed with various amounts of mant-dATP at pCa 9, 6, and 3, and the
fluorescence intensity was monitored over time. Single mixing stopped flow spectrofluorimetry
as used to observe the mant-dATP binding event (Scheme 1, page 36).
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Figure 15. Fast and slow phases of mant-dATP binding rate of cardiac myosin. (A) The analysis of the fast rate
obtained from the fluorescence traces of mant-dATP binding for cTnT-ND (n = 3 hearts, closed circle) and WT (n
= 4hearts, open circle) myofibrils against different ATP concentrations at different Ca 2+ concentrations (pCa 9,
pCa 6 and pCa 3). Data were fitted by a hyperbola. (B) The second order rate constant (K1k2) of mant-dATP binding
to myosin in the myofibrils was calculated at lower mant-dATP concentration (< 25 µM). (C) The slow phase of
mantdATP binding rates. The rates for cTnT-ND (red closed circle) and WT (black closed circle) myofibrils were
measured at three different pCa (9, 6, and 3). Red lines (cTnT-ND) and black lines (WT) are the average of all data
sets. Data represent means ± S.D.

The data at concentrations lower than 25 µM mant-dATP were well fit with single
exponential function while the data at higher mant-dATP concentrations were well fit with
double exponential function as determined by the r2 values.
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Figure 16. Representative traces of ADP dissociation by mant-dADP chase for cTnT-ND and WT
myofibrils. (A) Double mixing reactions were performed to measure the rate of ADP dissociation from
cardiac myosin in the myofibrils at 23°C. 0.5 µM myosin and 2 µM ADP were mixed and incubated for
20 sec in a delay line, and then the solution was mixed with 800 µM mant-dADP. (B) Typical traces of
ADP dissociation from myosin II in cTnT-ND (n = 4 hearts) and WT myofibrils (n = 4 hearts), at three
different pCas are shown. Blue line represents the time of the start. Each trace was averaged with four
different traces.
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7.2.4 DISSOCIATION OF ADP FROM MYOFIBRILAR MYOSIN II
The rate of ADP dissociation from actomyosin
in WT and cTnT-ND myofibrils can be measured by
the increase in FRET fluorescence after mixing a high
concentration of mant-dADP with myofibrillar
actomyosin-ADP. The fast and slow observed rate
constants (kobs) were extracted by fitting the
fluorescence signal with a double exponential (Eq. 2,
Figure 16). The dependence of kobs upon calcium

Figure 17. Fast and Slow phases of
ADP dissociation

concentration for both WT and cTnT-ND was fit to a
linear equation.

We also examined the rate of mant-dADP dissociation from actomyosin in WT and
cTnTND myofibrils from the decrease in FRET fluorescence after mixing myofibrillar
actomyosinmant-dADP with a high concentration of ADP (Fig. 18). The decreased fluorescence
signal induced by mant-dADP dissociating from myosin was fitted to a double exponential
equation (Eq. 2).
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Figure 18. Representative traces of mantdADP dissociation by ADP chase for
cTnTND and WT myofibrils. (A) Double
mixing reactions were performed to
measure the rate of ADP dissociation from
cardiac myosin in the myofibrils at 23°C.
0.5 µM myosin and 2 µM mant-dADP were
mixed and incubated for 20 sec in a delay
line, and then the solution was mixed with
1 mM mant-dADP. (B) Typical traces of
mant-dADP dissociation from myosin II in
cTnT-ND (n = 3 hearts) and WT myofibrils
(n = 4 hearts), at three different pCas are
shown. Blue line represents the time of
the stop. Each trace was averaged with
four different traces.

The slow rates of mant-dADP and ADP dissociation were calculated from data shown in
Figs. 16 and 18, respectively. The rates were not significantly different between the cTnT-ND and
WT myofibrils under all Ca2+ concentrations tested. The amplitude of the slow rates was less than
5% of the total amplitude of the fluorescence intensity, suggesting that the slow rate is due to a
small fraction of exchange between ADP binding and dissociation.
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Figure 19. Fast and Slow phases of mantdADP Dissociation

7.3 DISCUSSION
7.3.1 CTNT N-TERMINUS DOES NOT AFFECT THE CALCIUM SENSITIVITY OF MYOFIBRILAR ATPASE
cTnT differs from the fast and slow skeletal muscle TnI mainly by the N-terminal
extension75. During postnatal development of the heart and pathological adaptation, the
structure of TnT is regulated by alternative splicing76,77. Such regulatory modificatations suggest
important physiological functions.
To investigate the mechanistic basis for the regulatory function of the N-terminal
extension of cTnT, we studied the ATPase kinetics of myofibrils isolated from cTnT-ND and WT
mouse hearts. ATPase assay at various calcium concentrations showed that cTnT-ND myofibrils
at pCa 3, have lower maximum ATPase activity than the WT controls. Our data also shows no
significant change in the calcium sensitivity of myosin II ATPase when compared between
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cTnTND and WT myofibrils. Previous studies showed that the selective removal of the N-terminal
variable region of cTnT slightly decreases the maximum myosin II ATPase activity without
affecting the thin filament calcium sensitivity42,

78, 79.

Our results obtained from skinned

myofibrils isolated from frozen cardiac muscle are consistent with the previous data.
7.3.2 MANT-DATP BINDING
Mant-dATP binding rates from pCa 9 and pCa 3 did not show much of a difference. Thus,
we conclude that mant-dATP binding was not significantly affected by calcium concentration.
However, the maximum binding rate (k2) for cTnT-ND myofibrils was consistently lower than that
of WT myofibrils. We believe that this may be due to a lower number of actomyosin crossbridges
forming in cTnT-ND myofibrils. This lower number of crossbridges could be possibly due to a new
inhibitory affect cTnT-ND has on the thin filament.
Table 4: Parameter of mant-dATP Binding
cTnT-ND

WT

pCa

9

6

3

9

6

3

k2 (s-1)

37.0±0.51

39.2±4.82

59.1±6.25

90.0

63.1±2.21

108.0±16.5

K1 (mM-1)

25.6±12.5

25.6±8.16

16.6±0.4

16.7±11.25

15.4±1.45

10.0±0.79

K1k2 (µM-1s-1)

0.34±0.06

0.31±0.07

0.44±0.05

0.37±0.23

0.33±0.05

0.58±0.07

7.3.3 ADP AND MANT-DADP DISSOCIATION
We employed double-mixing stopped flow methods to investigate the effect of the Nterminal truncated cTnI on ADP dissociation from cardiac myosin in WT and cTnT-ND myofibrils
from pCa 9 to pCa 3. Together with the mant-dADP chasing results in Fig 13, the amplitudes of
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the slow rates were independent of pCa and were ~5% of total signal after the syringes stopped.
Thus, we conclude that the data represent true ADP dissociation events.
Our results in Fig. 14, Fig. 16, and Table 5 showed that the fast rates of ADP and mantdADP
dissociation from cTnT-ND myofibrils are calcium independent, whereas the rates of WT
myofibrils are faster and did not significantly change over calcium concentrations. As described
earlier, preceding studies have shown that the ADP dissociation rate from actomyosin is ~100fold
faster than that from myosin alone, meaning that thin filament binding to myosin accelerates
ADP dissociation 56, 62-65. Thus, the ADP dissociation rate depends on the number of cross-bridges
of actomyosin. Our results suggest that at all calcium concentrations, myosin heads in cTnT-ND
myofibrils may bind less to the thin filament than that in WT myofibrils since the rate of ADP and
mant-dADP dissociation is slower than that of WT. Our results also report no calcium
dependence of dissociation for both cTnT-ND and WT myofibrils. Therefore, the N-terminal
variable region of cardiac troponin T does not affect ADP dissociation events.
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7.4 COMPARISON OF CTNI-ND AND CTNT-ND EFFECTS ON THE ACTOMYOSIN ATPASE CYCLE
It’s been well studied that the proteolytic truncation of the N-terminal extension of
cardiac troponin I is a novel mechanism needed to regulate cardiac function during physiological
and stressed conditions. It’s also been well studied that the proteolytic truncation of the Nterminal extension of cardiac troponin T just minutes after myocardial ischemia reperfusion is a
novel mechanism to modify the myocardial contractile kinetics and increase the energetic
efficiency of the heart in order for the heart to sustain cardiac function during congestive heart
failure. However, there is no known literature stating a condition in which both cTnI and cTnT
N-terminal truncations can be induced at the same time. This probably indicates that it
physiologically does not make sense to truncate both cTnI and cTnT because the consequences
would be detrimental to cardiac function. Therefore, this may be an evolutionary effect in order
to protect the heart from becoming too weak
during stressed conditions.
In order to

understand

how

the

simultaneous truncations would affect the heart,
we need to compare how the N-terminal
extensions of cardiac troponin T and I affect the
actomyosin ATPase cycle. One of the biggest
Figure 20. Comparison between cTnT-ND, cTnIND and WT mant-dATP binding rate constants.

difference is how the N-terminal truncation
affects k2’, the rate of mant-dATP binding to

actomyosin. When compared to WT, the cTnI-ND drastically increases the maximum ATP binding
rate, while cTnT-ND decreases k2’ (Fig. 20). This may be due to the different functional effects that
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the N-terminus has on the thin filament. As stated above, it is unclear as to how many actomyosin
cross bridges are formed. However, our data may suggest that the removal of the N-terminus of
cTnI may facilitate more cross bridge formation, while the removal of the N-terminus of cTnT may
facilitate a decreased number of cross bridge formation, when compared to WT control. Previous
studies with rat cardiac troponin T have shown that while cross bridge recruitment dynamics is
modulated by the central region of cTnT, the N-terminal variable region has a synergistic effect on
the ability to modulate the recruitment of cross bridges80. This may be also evident from K1, the
equilibrium constant for the initial actomyosin complex formation. K1 for cTnT-ND is smaller than
WT at all calcium concentrations. This implies that cTnT-ND may exhibit an inhibitory effect on
crossbridge formation. This lower number of crossbridge formation could potentially explain

Figure 21. Comparison between cTnT-ND, cTnI-ND and WT ADP and mant-dADP release rate
constants. A.) ADP release and B.) mant-dADP release

the decreased contractile rate while no change in the pCa50 value is observed. However, further
investigation of the number of crossbridges formed is still needed.
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This theory may also be supported by the rate constants for ADP and mant-dADP
dissociation k5’ (Fig. 21). The rate of ADP and
mant-dADP dissociation is slower at all
calcium concentrations than that of WT
control, further suggesting that there are
less cross bridges participating in ADP/mantdADP dissociation.
Figure 22. Comparison between cTnT-ND, cTnIND and WT Pi release rate constants.

If we look at phosphate release, k6’,
(Fig. 22) the calcium response for WT and

cTnI-ND is evident. However, it seems that cTnT-ND myofibrils lost the calcium response to Pi
release, whereas the calcium response for cTnI-ND myofibrils was elevated. Therefore, our data
suggests that cTnT-ND decreases the dynamics of the allosteric response of the myofibrils to the binding
of calcium to cTnC.
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CHAPTER 8 CONCLUSION
While both cTnI-ND and cTnT-ND have been shown to have unique effects on the
actomyosin ATPase cycle, future work still needs to be done to further investigate phosphate
release from both cTnI-ND and cTnT-ND myofibrils. This will determine whether it is the rate
limiting step in the ATPase cycle. Studies to determine the number of crossbridges formed in each
system is also important to understand the inhibitory effect the deletion of the N-terminal of
cTnT has on the thin filament. These studies have contributed to the current knowledge we know
about these proteins and will help future plans to design a proper treatment for heart disease.
Future kinetic studies on transgenic mice expressing both cTnI-ND and cTnT-ND could be
useful to understand why both mutations never occur together in a diseased heart. We can
already hypothesize that both mutations would cause an extremely weak heart, however, the
mechanism and the effect on the actomyosin crossbridge kinetics is still to be determined.
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ABSTRACT
THE EFFECTS OF THE N-TERMINAL EXTENSIONS OF CARDIAC TROPONINS ON THE Ca2+
REGULATION OF MYOSIN ATPASE KINETICS IN CARDIAC MYOFIBRILS
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Contraction of cardiac muscle is the basis of heart function. Heart failure, i.e., weakened
contraction of cardiac muscle, is the most common cause of morbidity and mortality of heart
diseases. Cardiac muscle contraction is regulated by calcium via the function of troponin, a
protein complex associated with the myofilaments in muscle cells. The cardiac troponin subunits
T (cTnT) and I (cTnI) have unique N-terminal domains that can be selectively removed by
restrictive proteolysis during cardiac adaptation to physiological and pathological stresses,
indicating a role of these stuctures in modulating cardiac contraction. This study aims to
understand the effects of the N-terminal regulation of cTnT and cTnI on the actomyosin ATPase
kinetics in response to Ca2+ signal, which is the foundation of cardiac muscle power generation.
The ATP binding and ADP dissociation rates of the actomyosin ATPase of transgenic mouse
cardiac myofibrils containing cTnI lacking the N-terminal extension (cTnI-ND) have been
measured using stopped flowmetry with mant-dATP and mant-dADP, respectively. The results
showed that the second order mant-dATP binding rate for cTnI-ND myofibrils was three-fold as
fast as that of wild type myofibrils. Moreover, the ADP dissociation rate of cTnI-ND myofibrils was
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positively dependent on calcium concentrations, while the wild type controls were not
significantly affected. Further studies will be performed to determine the other steps of the
ATPase cycle in cTnI-ND myofibrils, as well as the kinetic properties of cardiac myofibrils of which
the N-terminal variable region of cTnT has been genetically removed. The anticipated results will
determine the rate-limiting steps of actomyosin ATPase cycle that are regulated by the Nterminal extensions of cTnI and cTnT.
Completion of the proposed study will lead to new understanding of the function of the
N-terminal segments of cTnI and cTnT as well as troponin-tropomyosin-mediated regulation of
cardiac muscle contraction, which in turn, may provide useful information for the development
of new treatment for heart failure.
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